Thurston Springer Miller Herd & Titak Inc. Increases Holdings in Cencora, Inc. (NYSE:COR)

Thurston Springer Miller Herd & Titak Inc. lifted its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 22.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,661 shares of the company's stock after buying an additional 1,613 shares during the period. Thurston Springer Miller Herd & Titak Inc.'s holdings in Cencora were worth $2,408,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. DAVENPORT & Co LLC boosted its stake in shares of Cencora by 2.2% in the 4th quarter. DAVENPORT & Co LLC now owns 5,509 shares of the company's stock worth $1,238,000 after buying an additional 120 shares during the last quarter. Stock Yards Bank & Trust Co. bought a new position in Cencora in the fourth quarter valued at about $290,000. Mather Group LLC. boosted its position in Cencora by 2.3% in the fourth quarter. Mather Group LLC. now owns 2,615 shares of the company's stock worth $588,000 after purchasing an additional 58 shares during the last quarter. E. Ohman J or Asset Management AB grew its stake in shares of Cencora by 4.0% during the 4th quarter. E. Ohman J or Asset Management AB now owns 7,800 shares of the company's stock valued at $1,753,000 after purchasing an additional 300 shares during the period. Finally, Stratos Wealth Partners LTD. purchased a new stake in shares of Cencora during the 4th quarter valued at about $205,000. 97.52% of the stock is currently owned by institutional investors.

Insider Activity at Cencora

In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This trade represents a 9.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the sale, the chief executive officer now directly owns 47,582 shares in the company, valued at $13,766,900.06. This trade represents a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,253 shares of company stock valued at $11,102,417. Corporate insiders own 10.80% of the company's stock.

Wall Street Analyst Weigh In

COR has been the subject of several recent research reports. Bank of America boosted their target price on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Morgan Stanley set a $288.00 price objective on shares of Cencora in a research report on Tuesday, April 15th. Citigroup raised their target price on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $274.00 to $337.00 in a research report on Tuesday. Finally, UBS Group raised their price objective on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, Cencora presently has an average rating of "Moderate Buy" and an average target price of $306.91.

Cencora Price Performance

Shares of Cencora stock traded up $0.60 during trading hours on Friday, hitting $289.01. The company's stock had a trading volume of 1,302,615 shares, compared to its average volume of 1,529,612. The company has a market cap of $56.02 billion, a PE ratio of 41.11, a PEG ratio of 1.31 and a beta of 0.58. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The business has a 50 day moving average price of $286.06 and a two-hundred day moving average price of $259.82. Cencora, Inc. has a 12-month low of $218.65 and a 12-month high of $309.35.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. During the same quarter last year, the company earned $3.80 EPS. The firm's quarterly revenue was up 10.3% on a year-over-year basis. Analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.76%. Cencora's payout ratio is 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.